A multicenter retrospective observational study of Axi-cel or Tisa-cel in a real-world setting for hematotoxicity in patients with relapsed/refractory large B-cell lymphoma
Latest Information Update: 06 Jul 2021
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Acronyms CAR-HEMATOTOX
- 06 Jul 2021 New trial record
- 24 Jun 2021 Results (n=235) published in the Blood.